COMMUNIQUÉS West-GlobeNewswire

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
04/11/2025
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment [...]
Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®
04/11/2025
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus [...]
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
04/11/2025
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit [...]
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
04/11/2025
– Mean weight loss of 19.2% I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6% I at 8 mg [...]
Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference
04/11/2025
CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at [...]
Fueling Discovery: Misophonia Research Fund Launches New Team Science Award, Expands 2026 Funding Opportunities, and Announces Latest Grantee Cohort
04/11/2025
CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Misophonia Research Fund (MRF), an initiative of the REAM Foundation, announces a major expansion of its support of misophonia research – launching the first-ever team [...]
Édition 2025 du congrès mondial du collectif médical polonais « Save a Life » : une mission d’envergure mondiale répondant à l’objectif de faire progresser l’expertise en sauvetage de vies
04/11/2025
Un rassemblement des professionnels de santé polonais répartis à travers le monde placé sous le signe de la coopération internationale et de l’excellence médicale VARSOVIE, Pologne, 04 nov. 2025 (GLOBE NEWSWIRE) -- Du [...]
Bionet Launches O’Pet Curv: A New Standard in Veterinary Wireless Monitoring
04/11/2025
TUSTIN, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bionet America, Inc ., a leader in veterinary medical devices, has introduced the new O’Pet Curv, a compact, cloud-connected wireless monitoring system that allows [...]
Coloplast Finance B.V. - Annual Report, 2024/25
04/11/2025
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
04/11/2025
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other [...]
Equillium to Participate in Upcoming Investor Conferences
04/11/2025
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
04/11/2025
Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
04/11/2025
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing [...]
Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year
04/11/2025
C ompany Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and [...]
Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7% — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $ [...]
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
04/11/2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American [...]
CVRx to Present at the Jefferies Global Healthcare Conference in London
04/11/2025
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
04/11/2025
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPs SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company [...]

Pages